Q1 2024 Holdings
Filed 2024-05-15 | 46 holdings | $8.6B | 13F-HR | View on SEC ↗ · Holdings Table ↗
Sign in to see sub-manager breakdown
| Issuer | Class | CUSIP | Value ↓ | Shares | % Portfolio |
|---|---|---|---|---|---|
| United Therapeutics Corp(UTHR) | Common | 91307C102 | $656.7M | 2,858,888 | 7.7% |
| Apellis Pharmaceuticals Inc(APLS) | Common | 03753U106 | $653.1M | 11,111,111 | 7.6% |
| Ascendis Pharma(ASND) | Sponsored ADR | 04351P101 | $599.6M | 3,966,666 | 7.0% |
| Sarepta Therapeutics Inc(SRPT) | Common | 803607100 | $562.4M | 4,344,444 | 6.6% |
| Madrigal Pharmaceuticals Inc(MDGL) | Common | 558868105 | $519.2M | 1,944,444 | 6.1% |
| Argenx SE(ARGX) | Sponsored ADR | 04016X101 | $487.6M | 1,238,467 | 5.7% |
| Krystal Biotech Inc(KRYS) | Common | 501147102 | $454.7M | 2,555,555 | 5.3% |
| Spdr Series Trust - S&P Biotech(XBI) | ETF | 78464A870 | $408.0M | 4,300,000 | 4.8% |
| Biomarin Pharmaceutical Inc(BMRN) | Common | 09061G101 | $381.2M | 4,365,000 | 4.4% |
| Amicus Therapeutics Inc(FOLD) | Common | 03152W109 | $322.8M | 27,400,000 | 3.8% |
| Cerevel Therapeutics Hldng(CERE1EUR) | Common | 15678U128 | $319.4M | 7,555,555 | 3.7% |
| Viking Therapeutics Inc(VKTX) | Common | 92686J106 | $294.4M | 3,590,000 | 3.4% |
| Arrowhead Pharmaceuticals Inc(ARWR) | Common | 04280A100 | $244.7M | 8,555,555 | 2.9% |
| Xenon Pharmaceuticals Inc(XENE) | Common | 98420N105 | $243.9M | 5,666,666 | 2.8% |
| Alpine Immune Sciences Inc(NVLSEUR) | Common | 02083G100 | $228.9M | 5,775,000 | 2.7% |
| Vera Therapeutics Inc(VERA) | Common | 92337R101 | $227.0M | 5,265,000 | 2.6% |
| Iovance Biotherapeutics Inc(IOVA) | Common | 462260100 | $173.4M | 11,700,000 | 2.0% |
| Intra-Cellular Therapies Inc(ITCIEUR) | Common | 46116X101 | $171.3M | 2,475,000 | 2.0% |
| Kymera Therapeutics Inc(KYMR) | Common | 501575104 | $156.3M | 3,888,888 | 1.8% |
| Avidity Biosciences Inc(RNA) | Common | 05370A108 | $148.7M | 5,825,000 | 1.7% |
| Moonlake Immunotherapeutics(MLTX) | CLASS A ORD | 61559X104 | $129.6M | 2,580,000 | 1.5% |
| Syndax Pharmaceuticals Inc(SNDX) | Common | 87164F105 | $100.5M | 4,222,222 | 1.2% |
| Macrogenics Inc(MGNX) | Common | 556099109 | $90.5M | 6,150,000 | 1.1% |
| Kura Oncology Inc(KURA) | Common | 50127T109 | $82.1M | 3,850,000 | 1.0% |
| Autolus Therapeutics PLC(AUTL) | Sponsored ADR | 05280R100 | $78.8M | 12,345,678 | 0.9% |
| Spyre Therapeutics Inc(SYRE) | Common | 00773J202 | $69.8M | 1,839,138 | 0.8% |
| Soleno Therapeutics Inc(SLNO) | Common | 834203309 | $69.6M | 1,625,000 | 0.8% |
| Biocryst Pharmaceuticals Inc(BCRX) | Common | 09058V103 | $66.3M | 13,050,000 | 0.8% |
| Ocular Therapeutix Inc(OCUL) | Common | 67576A100 | $65.1M | 7,148,936 | 0.8% |
| Taysha Gene Therapies Inc(TSHA) | Common | 877619106 | $53.5M | 18,650,000 | 0.6% |
| Tourmaline BIO Inc(TRML) | Common | 89157D105 | $50.9M | 2,222,222 | 0.6% |
| Roivant Sciences LTD(ROIV) | Common | G76279101 | $49.0M | 4,651,162 | 0.6% |
| Alnylam Pharmaceuticals Inc(ALNY) | Common | 02043Q107 | $44.8M | 300,000 | 0.5% |
| Mannkind Corp(MNKD) | Common | 56400P706 | $40.8M | 9,000,000 | 0.5% |
| Merus N V | Common | N5749R100 | $40.0M | 888,888 | 0.5% |
| Vaxcyte Inc(PCVX) | Common | 92243G108 | $39.3M | 575,000 | 0.5% |
| Ultragenyx Pharmaceutical Inc(RARE) | Common | 90400D108 | $38.8M | 830,000 | 0.5% |
| Marinus Pharmaceuticals Inc(MRNS*) | Common | 56854Q200 | $37.4M | 4,140,607 | 0.4% |
| Rocket Pharmaceuticals Inc(RCKT) | Common | 77313F106 | $34.0M | 1,260,900 | 0.4% |
| Monte Rosa Therapeutics Inc(GLUE) | Common | 61225M102 | $32.0M | 4,535,000 | 0.4% |
| CG Oncology Inc(CGON) | Common | 156944100 | $30.7M | 700,000 | 0.4% |
| Crispr Therapeutics AG(CRSP) | Common | H17182108 | $28.6M | 419,580 | 0.3% |
| Verrica Pharmaceuticals Inc | Common | 92511W108 | $23.7M | 3,999,999 | 0.3% |
| Kyverna Therapeutics Inc(KYTX) | Common | 501976104 | $11.8M | 475,000 | 0.1% |
| Aadi Biosciences Inc(WHWK) | Common | 00032Q104 | $6.7M | 2,849,402 | 0.1% |
| Adverum Biotechnologies Inc(AVU0) | Common | 00773U207 | $5.9M | 416,666 | 0.1% |